Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

545 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.
Choi JG, Winn AN, Skandari MR, Franco MI, Staab EM, Alexander J, Wan W, Zhu M, Huang ES, Philipson L, Laiteerapong N. Choi JG, et al. Among authors: philipson l. Ann Intern Med. 2022 Oct;175(10):1392-1400. doi: 10.7326/M21-2941. Epub 2022 Oct 4. Ann Intern Med. 2022. PMID: 36191315 Free PMC article.
The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: a Systematic Review and Meta-Analysis.
Alexander JT, Staab EM, Wan W, Franco M, Knitter A, Skandari MR, Bolen S, Maruthur NM, Huang ES, Philipson LH, Winn AN, Thomas CC, Zeytinoglu M, Press VG, Tung EL, Gunter K, Bindon B, Jumani S, Laiteerapong N. Alexander JT, et al. Among authors: philipson lh. J Gen Intern Med. 2022 Feb;37(2):415-438. doi: 10.1007/s11606-021-07105-9. Epub 2021 Sep 10. J Gen Intern Med. 2022. PMID: 34508290 Free PMC article.
Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: a Systematic Review and Meta-analysis.
Alexander JT, Staab EM, Wan W, Franco M, Knitter A, Skandari MR, Bolen S, Maruthur NM, Huang ES, Philipson LH, Winn AN, Thomas CC, Zeytinoglu M, Press VG, Tung EL, Gunter K, Bindon B, Jumani S, Laiteerapong N. Alexander JT, et al. Among authors: philipson lh. J Gen Intern Med. 2022 Feb;37(2):439-448. doi: 10.1007/s11606-021-07227-0. Epub 2021 Nov 30. J Gen Intern Med. 2022. PMID: 34850334 Free PMC article.
Approach to the Patient with MODY-Monogenic Diabetes.
Broome DT, Pantalone KM, Kashyap SR, Philipson LH. Broome DT, et al. J Clin Endocrinol Metab. 2021 Jan 1;106(1):237-250. doi: 10.1210/clinem/dgaa710. J Clin Endocrinol Metab. 2021. PMID: 33034350 Free PMC article. Review.
Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts.
Voss MG, Cuthbertson DD, Cleves MM, Xu P, Evans-Molina C, Palmer JP, Redondo MJ, Steck AK, Lundgren M, Larsson H, Moore WV, Atkinson MA, Sosenko JM, Ismail HM; DPT-1 and TrialNet Study Groups. Voss MG, et al. Diabetes Care. 2021 Oct;44(10):2329-2336. doi: 10.2337/dc21-0226. Epub 2021 Aug 6. Diabetes Care. 2021. PMID: 34362815 Free PMC article. Clinical Trial.
545 results